<DOC>
	<DOCNO>NCT01714570</DOCNO>
	<brief_summary>Neutropenia common patient receive hematopoietic stem cell transplantation , median duration 14 day . In 2010 update , IDSA recommend Piperacillin/tazobactam first-line mono-therapy febrile patient neutropenia high risk . In china , data piperacillin/tazobactam febrile neutropenia hematopoietic stem cell transplantation limit . The current study evaluate efficacy piperacillin/tazobactam compare imipenem/cilastatin febrile neutropenia transplantation .</brief_summary>
	<brief_title>Piperacillin/Tazobactam Empirical Therapy Febrile Neutropenia</brief_title>
	<detailed_description>1 . Swab culture ( skin , pharyngeal , nasal , anus ) administer laminar flow room transplantation . 2 . Randomize febrile patient 2 group . 3 . Therapy group receive piperacillin/tazobactam , 4.5g q6h iv . Control group receive imipenem/cilastatin , 0.5g q6h . Duration 5-10 day .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>Age 1365 year receive Autologous Allogeneic hematopoietic stem cell transplantation . ECOG score 01 . ICF available . Allergic therapy drug . Documented infection neutropenia . Renal dysfunction . Suffering central nervous system mental disease .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>